Kiadis Pharma is a clinical stage biopharmaceutical company
developing innovative and potentially life‑saving therapies for
patients with late stage blood cancers and related disorders in
need of a transplant, an area of significant unmet medical need.
The Company is currently sponsoring a multi‑center Phase II
clinical trial for its lead product ATIR™ and is collaborating with with renowned centers in Europe and North America.
September 3, 2014Kiadis Pharma appoints Jeroen Rovers as its Chief Medical Officer
March 24, 2014Kiadis Pharma organizes a satellite symposium on March 30, 2014 at the 40th Annual Meeting of the European Society for Blood and Marrow Transplantation
January 29, 2014Kiadis Pharma initiates collaboration for personalized immunotherapies using ATIR™ with Technische Universität München
December 5, 2013Kiadis Pharma participates in haploidentical transplantation 2013 Forum
Click to download the Company Fact Sheet which provides a valuable insight into where Kiadis Pharma stands today. It summarizes what the Company's lead product ATIR™ is about, its market potential and the progress that is being made in clinical development.
Kiadis Pharma features in Nature’s Biopharma Dealmakers edition of September 2014.
ATIR™ Phase I/II study completed
5‑year follow‑up of patients with high‑risk malignancies from Phase I/II clinical study confirms long‑term safety and efficacy of ATIR™ over a broad dose range.
EPIC Biotech Conference
October 2, 2014 - London, United Kingdom